Press releases
- Quest Diagnostics to Acquire PathAI Diagnostics to Accelerate AI and Digital Pathology Adoption in Cancer Diagnosis; Forms Licensing Agreements with PathAI
- Quest Diagnostics Reports First Quarter 2024 Financial Results; Raises Guidance for Full Year 2024
- Quest Diagnostics Adds p-tau217 Blood Biomarker Testing to Suite of Services Designed to Assess Risk and Help Aid Diagnosis of Alzheimer's Disease
- Quest Diagnostics and Broad Clinical Labs to Evaluate Whole Genome Sequencing as First-Line Genetic Test for Developmental Delay
- Study in Frontiers in Neurology Affirms Amyloid Blood Test Can Help Identify Patients Who May Forgo Imaging Evaluation for Alzheimer's Disease
- Quest Diagnostics to Release First Quarter 2024 Financial Results on April 23, 2024
- Quest Diagnostics to Speak at the Barclays 26th Annual Global Healthcare Conference
- Quest Diagnostics and Instacart Collaborate to Reduce Food Insecurity Across the United States with Integrated Patient Health Coaching and Nutritious Grocery Delivery
- Freenome Raises $254 Million in New Funding to Accelerate its Platform for Early Cancer Detection
- Quest Diagnostics Debuts MelaNodal Predict™ Test, Personalizing Melanoma Risk Prediction to Help Patients Forgo Invasive Surgery
More ▼
Key statistics
As of last trade Quest Diagnostics Inc (DGX:DEU) traded at 127.70, -2.78% below its 52-week high of 131.35, set on Jun 23, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 128.85 |
---|---|
High | 128.85 |
Low | 127.50 |
Bid | 126.65 |
Offer | 127.60 |
Previous close | 129.55 |
Average volume | 57.78 |
---|---|
Shares outstanding | 111.09m |
Free float | 110.62m |
P/E (TTM) | 18.35 |
Market cap | 15.15bn USD |
EPS (TTM) | 7.43 USD |
Annual div (ADY) | 2.77 EUR |
---|---|
Annual div yield (ADY) | 2.17% |
Div ex-date | Apr 05 2024 |
Div pay-date | Apr 22 2024 |
Data delayed at least 15 minutes, as of May 02 2024.
More ▼